期刊文献+

慢性复发性丙型肝炎的优化治疗疗效分析与比较

Analysis and comparison in optimized treatment of chronic recurrent hepatitis C
下载PDF
导出
摘要 目的研究探讨慢性复发性丙型肝炎的优化治疗方案及其最新研究。方法选择2008年5月至2012年5月至该院传染病科就诊的慢性复发性丙肝的患者50例,分为两组,每组25例,甲组采用标准治疗延长疗程方案,乙组采用标准治疗加大剂量方案,通过观察两组的持续病毒学应答(SVR)来比较两组治疗方法的效果,并观察6个月后的复发情况。结果甲组获得32%的SVR率,乙组获得23%的SVR率;6个月后甲组的复发率为38%,乙组为43%,差异均有统计学意义(P<0.05)。结论甲组的标准治疗延长疗程方案的临床SVR率高于乙组。 Objective To optimize the treatment of chronic hepatitis C recurrence.Methods During May 2008 to May 2012,50 patients with chronic recurrent hepatitis C were chosen in the infectious department of our hospital.They were divided into two groups with 25 cases in each group.Group A was treated by standard extended treatment scheme,while Group B was treated by standard large dose scheme.The effect was estimated by the observation of sustained virologic response in the two groups(sustained virologic response,SVR).Results 32% SVR rate was found in group A and 23% SVR rate was found in Group B.38%recurrence rate appeared in group A after six months and 43% recurrence rate occurred in group B,there were significant difference between two groups(P〈0.05).Conclusion The standard extended treatment schemes of pegylated interferon and ribavirin is superior to group B in SVR rate.
出处 《重庆医学》 CAS 北大核心 2015年第23期3218-3220,共3页 Chongqing medicine
关键词 复发性丙型肝炎 优化治疗 复发率 疗效分析 recurrent hepatitis C optimal treatment recurrence rate efficacy
  • 相关文献

参考文献5

二级参考文献56

  • 1Meetings[J].World Journal of Gastroenterology,2010,16(1). 被引量:25
  • 2魏来.丙型肝炎研究进展[J].中国继续医学教育,2010,2(3):9-17. 被引量:10
  • 3Giada Sebastiani,Alfredo Alberti.Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy[J].World Journal of Gastroenterology,2006,12(23):3682-3694. 被引量:33
  • 4Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update[J]. Hepatology, 2009,49(4): 1335-1374.
  • 5McCaughan GW, Omata M, Amarapurkar D, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection[J]. J Gastroenterol Hepatol,2007,22(5): 615-633.
  • 6Gordon SC. Treatment of viral hepatitis-2001 [J]. Ann Med, 2001,33(6):385-390.
  • 7Pawlotsky JM. Treating hepatitis C in "difficult-to-treat" patients[J]. N Engl J Med, 2004,351 (5):422-423.
  • 8Fried MW, Jensen DM, Rodriguez-Torres M, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin[J]. Hepatology,2008,48(4): 1033-1043.
  • 9Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? [J]. Liver Int,2009,29(Suppl 1):S15-S18.
  • 10Farnik H, Mihm U ,Zeuzem S. Optimal therapy in genotype 1 patients[J]. Liver Int, 2009,29(Suppl 1):S23-S30.

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部